ライフサイエンスコーパス: transfusion reaction

1 tologous CD4 T cells and was attributed to a transfusion reaction.

2 Twenty-two (1.1%) had delayed serologic transfusion reaction.

3 n TRALI or control PCs that did not elicit a transfusion reaction.

4 lood itself, or the probability or extent of transfusion reaction.

5 can cause life-threatening delayed hemolytic transfusion reactions.

6 ating a risk for Vel blood typing errors and transfusion reactions.

7 eic plasma carries with it risks for adverse transfusion reactions.

8 sociated with laboratory evidence of delayed transfusion reactions.

9 ibodies to HNA-2a frequently cause pulmonary transfusion reactions.

10 177, and the role of antibodies to HNA-2a in transfusion reactions.

11 blood components frequently causes pulmonary transfusion reactions.

12 pansion as well as the risk of infection and transfusion reactions.

13 smission, and recurrent febrile nonhemolytic transfusion reactions.

14 that could lead to immune mediated hemolytic transfusion reactions.

15 ew opportunistic event/death or frequency of transfusion reactions.

16 e antigenic determinants, thereby minimizing transfusion reactions.

17 t time of transfusion and review of reported transfusion reactions.

18 ll as the signs, symptoms, and management of transfusion reactions.

19 A total of 284 transfusion reactions (0.55%) were reported by passive s

20 prophylactic use and treatment of hemolytic transfusion reactions and complement-mediated hemolytic

21 including life-threatening delayed hemolytic transfusion reactions and difficulty in finding compatib

22 nically significant problem that can lead to transfusion reactions and difficulty in locating future

23 te red blood cell (RBC) destruction, causing transfusion reactions and hemolytic anemia.

24 at block antibody binding in the settings of transfusion reactions and hemolytic disease of the newbo

25 against RBC non-ABO Ags can cause hemolytic transfusion reactions and limit availability of compatib

26 usion requirements, the incidence of delayed transfusion reactions, and de novo abs after transplant

27 for the specific management of anaphylactic transfusion reactions are contradictory as to the utilit

28 Transfusion reactions are often mediated by cytokines in

29 solution, designed to reduce plasma-related transfusion reactions, are also increasingly available b

30 fusion, particularly hepatitis and hemolytic transfusion reactions, became increasingly evident.

31 p erythrocytes may pose a risk for hemolytic transfusion reactions due to their elevated PX2 levels.

32 Hemolytic transfusion reactions (HTRs) are potentially fatal compl

33 Hemolytic transfusion reactions (HTRs) can produce serious and pot

34 Hemolytic transfusion reactions (HTRs) due to incompatible red blo

35 he pathophysiology of IgG-mediated hemolytic transfusion reactions (HTRs), and deeper understanding i

36 related acute lung injury (TRALI), hemolytic transfusion reactions (HTRs), and transfusion-associated

37 echanisms that can trigger delayed hemolytic transfusion reactions in sickle cell disease, and we des

38 cidence of allergic and nonhemolytic febrile transfusion reactions in two large studies.

39 Thus, understanding of hemolytic transfusion reactions is generated through clinical case

40 Some hemolytic transfusion reactions may have serious sequelae includin

41 he probability of life-threatening hemolytic transfusion reactions, not all patients generate anti-RB

42 No transfusion reactions or any serious adverse event was r

43 support; length of stay in the hospital; and transfusion reactions) or in the subgroup analyses.

44 the impact on infectious complications, (2) transfusion reaction rate, (3) leukodepletion, (4) reduc

45 lood induce antibody responses and hemolytic transfusion reactions similar to those seen in patients.

46 Septic transfusion reactions (STRs) resulting from transfusion

47 ctoriness to transfusions, alloimmunization, transfusion reactions, the transmission of infectious ag

48 ion of incompatible blood, acute and delayed transfusion reactions, transfusion-related acute lung in

49 nd management of each diagnostic category of transfusion reaction using evidence-based recommendation

50 Transfusion reactions were fewer following PCT platelets

51 Antibody-induced hemolytic transfusion reactions were first described over 300 year